Our previous study showed that J558 myeloma cells engineered CD40L lost their tumorigenicity in syngeneic mice, and the inoculation of J558/CD40L tumor cells further led to the protective immunity against wild tumors. In the present study, we investigated whether the vaccine can exert more efficient antitumor immunity by combination with adenovirus mediated CD40L gene therapy and immature dendritic cells (iDCs). The results demonstrated that intratumoral administration of iDCs 2 days after AdVCD40L injection, not only significantly suppressed the tumor growth, but also eradiated the established tumors in 40% of the mice. The potent antitumor effect produced by the combination therapy correlated with high expression of MHC, costimulatory and Fas molecules on J558 cells, which was derived from CD40L transgene expression. In addition, transgene CD40L expression could dramatically induce J558 cell apoptosis. Effectively capturing apoptotic bodies by iDCs in vivo could induce DC maturation, prime tumor-specific CTLs and tend to Th1-type immune response. Finally, in vivo depletion experimentation suggested both CD4 þ and CD8 þ T cells were involved in mediating the antitumor immune responses of combined treatment of AdVCD40L and iDCs, with CD8 þ T cells being the major effector. These findings could be beneficial for designing strategies of DCs vaccine and CD40L for anticancer immunotherapy.
D endritic cells (DCs) are the most potent antigenpresenting cells (APC) for the initiation of antigen (Ag)-specific immune responses. They migrate as precursors from the bone marrow into various organs, where they usually reside in an immature state. Within the internal organs, they can efficiently capture and process Ag. 1 Upon activation, they undergo a differentiation process that results in decreased Ag-processing capacity, enhanced expression of major histocompatibility complex (MHC) class I and class II, costimulatory and adhesion molecules, and upregulated chemokine receptor CCR7. These cells then migrate to secondary lymphoid tissues to interact with and activate naive T cells. 2 Based on the potent Ag-presenting ability of immature DCs (iDCs) and particular initiating T cells response capacity of mature DCs (mDCs), an important avenue of investigation is their potential in modulating immune functions such as the induction of tumor immunity. Many reports have shown that DCs pulsed with tumor-derived MHC class I-restricted peptides or tumor lysates are able to induce significant cytotoxic T lymphocyte (CTL)-dependent antitumor immune responses in vitro as well as in vivo. 3, 4 It has been illustrated that the functions of DCs, including Ag capture, Ag presentation and migration, change dynamically with their maturation. 5, 6 Among multitudinous stimuli for DC maturation, CD40L is one of the most important molecules. The major CD4 þ T-cell help signal for DC maturation is provided by the interaction between CD40L on activated CD4
þ T cells and CD40 expressed on DCs. [7] [8] [9] It has been demonstrated that mice lacking CD40L resulted in immunodeficiency accompanied by an impaired migration of DCs into secondary lymphoid tissues. 10 Thus, CD40 stimulation for DCs maturation is indispensable. It is well known that an effective antitumor immunity requires CD8 þ T cells recognizing tumor Ag-peptides bound to MHC class I expressed on tumor cells. However, CD8
þ T cells require presentation of Ag, by DCs receiving CD4 þ T-cell help signal, to acquire the ability to destroy the tumor cell.
induce CTL cytotoxicity. However, the most suitable conditioning of DCs for anticancer immunotherapy is not entirely clear. Watanabe et al 15 found that iDCs could provide significant advantages in anticancer immunotherapy rather than mDCs due to their ability to prime T cells in secondary lymphoid organs through immobilized anti-CD40 antibody stimulation model in vitro.
Several reports have shown that the CD40L interaction with the CD40 receptor expressed on the myeloma cell surface induced them to undergo growth arrest [16] [17] [18] [19] or apoptosis. 20 This effect is significantly enhanced by Apo-1/Fas (CD95) ligation. 21 Our previous study also confirmed that vaccination with CD40L-transduced J558 myeloma tumor cells lead to the production of protective immunity against wild-type J558 tumors. 22 Therefore, we hypothesized that intratumor injection of AdVCD40L might inhibit J558 tumor growth and induce tumor cell apoptosis. iDCs were then injected into tumor tissues to phagocytose the apoptotic cells or apoptotic bodies. CD40L expressed in the tumor microenvironment could stimulate the iDCs that had engulfed the apoptotic bodies to migrate to the lymph nodes and mature, enabling them to effectively prime and activate T lymphocytes. In this study, we investigated the strategy using intratumoral injection iDCs following adenovirus vector mediated CD40L gene therapy (AdVCD40L) to induce antitumor immunity in an established myeloma model. The results demonstrated that J558 cells treated in vitro with AdVCD40L induced high expression of MHC II, CD40, CD80, CD86 and Fas molecules, and apoptosis of J558 tumor cells. Moreover, intratumoral treatment with iDCs 2 days after AdVCD40L injection could enhance antitumor efficacy to established myeloma.
Materials and methods

Antibodies, cytokines, cell lines and mice
Rat monoclonal antibodies Gk1. 5 (anti-CD4) and 3.155 (anti-CD8) were purified by affinity chromatography from the respective hybridoma ascites. These two hybridoma cell lines were purchased from American Type Culture Collection (ATCC) (Rockville, MD). Biotinconjugated anti-mouse MHC class I (H-2K d ), MHC class II (I-A d ), CD4, CD8, CD25, CD40, CD40L, CD54 (ICAM-1), CD80, CD86, Fas and FasL antibodies as well as fluorescein isothiocyanate (FITC)-Annexin V and propidium iodide were all purchased from BD-Biosciences (Mississauga, Ontario, Canada). FITC-conjugated or phycoerythrin (PE)-conjugated avidin was obtained from Caltag (Burlingame, CA). Recombinant mouse interleukin (IL)-4, and granulocyte-macrophage colony stimulation factor (GM-CSF) were purchased from Peprotech (Ottawa, Ontario, Canada). J558 and SP2/0, which are both poorly immunogenic mouse myeloma cell lines, were obtained from ATCC, and maintained in Dubecco's modified Eagle's medium (DMEM) containing 10% fetal calf serum (FCS), penicillin and streptomycin (100 mg/ml). Female BALB/c mice (4-6 weeks old) were obtained from a breeding colony at the Animal Resource Center, University of Saskatchewan and maintained in our animal facility at the Saskatoon Cancer Center. Following receipt of approval by the Animal Care Ethics Review Committee, experiments were conducted according to the Guidelines of the Canadian Council for Animal Care.
Recombinant adenoviral vectors
A 1 kb cDNA fragment coding of the full open-reading frame of mouse CD40L gene was cloned by reverse transcription-polymerase chain reaction (RT-PCR) from a cDNA library of Con A-stimulated mouse spleen T cells using the Taq I polymerase. Two primers specific for the mouse CD40L gene were used, namely, the sense primer (5 0 ctcca ttggc tctag attcc 3 0 ) and the antisense primer (5 0 cctca tgagc cacat aatac 3 0 ). The cloned cDNA fragment was ligated into the pCR2.1 vector (Invitrogene, Carlsbed, CA) to form pCR2.1-CD40L. The CD40L sequence was verified by dideoxy nucleotide sequencing method. The cDNA fragment of CD40L (Xba I/Hind III) from the pCR2.1-CD40L vector was further ligated into the pLpA to form the adenoviral vector pLpA-CD40L. Construction of recombinant adenovirus AdV-CD40L from pLpA-CD40L and pJM17 vectors was performed as previously described. 23 The adenoviruses AdV-LacZ expressing the Escherichia coli b-galactosidase and AdVpLpA (i.e., with no gene insert) were used as marker and control adenoviral vector, respectively. These E1-deleted replication-deficient recombinant adenoviruses were amplified in 293 cell line (adenoviral E1 transformed human embryonic kidney cells), under the control of cytomegalovirus (CMV) early/immediate promoter/enhancer purified by cesium chloride ultracentrifugation and stored at À801C.
Genetic modification of tumor cells
To assess the susceptibility of J558 tumor cells to adenoviral infection, serial dilutions of AdVLacZ stock (2 Â 10 10 PFU/ml) were added to J558 cells seeded in triplicate in 96-well plates (1 Â 10 5 cells/well) to form different multiplicities of infection (MOI). The procedure has been described previously. 24 To determine b-galactosidase expression, the cells were fixed in formaldehyde/ glutaraldehyde, then stained and counterstained with X-gal and nuclear fast red, respectively. The proportions of positive (blue-staining) cells were determined from triplicate wells and taken as the percentage of transfection. Control J558 cells transfected with AdVpLpA did not exhibit any intrinsic b-galactosidase activity or falsepositive staining. We observed a dose-dependent response to the infecting dose of adenovirus, with maximal staining (70%) at MOI 200. Therefore, MOI 200 was selected for transfection of J558 cells with AdVCD40L or AdVpLpA in this study. J558 cells transfected with AdVCD40L or the control AdVpLpA were termed J558/CD40L or J558/ pLpA, respectively.
Generation of immature dendritic cells
The iDCs were prepared as described by Song et al. 25 Briefly, BM cells prepared from femora and tibiae of normal BALB/c (H-2K d ) mice were depleted of red blood cells with 0.84% ammonium chloride and plated in DC culture medium (DMEM plus 10% FCS, GM-CSF (2 ng/ ml)). On Day 3, nonadherent granulocytes, T and B cells were gently removed and fresh media added. On Day 4, the immature, nonadherent cells were harvested and used for intratumoral injection or in vitro cocultured with J558 cells that had been infected by AdV-CD40L for 24 hours.
Cocultivation of iDCs with J558 tumor cells
The iDCs were harvested and cocultured with J558 tumor cells. Briefly, DCs were mixed (1:1 ratio) with untransfected J558 cells, J558/pLpA or J558/CD40L which were irradiated before culture with iDCs. At 48 hours after cocultivation, the DCs were collected and used for immunophenotypic and endocytic analysis and mixed lymphocyte reaction (MLR).
MLR
Primary MLR were performed as previously described. 26 DCs were obtained after 48 hours of coculture with untransfect or transfected J558 cells. Graded doses of irradiated DCs (3000 cGy) were cocultured in 96-well plates with 2 Â 10 5 of autologous T cells from BALB/c mice. After 2 days, T-cell proliferation was measured using an overnight 
Phenotypic characterization of tumor cells, DCs and activated T cells
For phenotypic analysis, gene modified or unmodified J558 were stained for 1 hour on ice with the biotinconjugated rat anti-mouse antibodies (5 mg/ml each) specific for H-2Kd, I-Ad, Fas, CD40, CD40L, CD80 or CD86. The cells were then washed three times with PBS prior to incubation for an additional hour on ice with FITC or PE-conjugated avidin. After three more washes with PBS, the cells were then analyzed by flow cytometry. Isotype-matched monoclonal antibodies were used as controls.
At 48 hours after cocultivation with irradiated gene modified or unmodified J558 cells, the phenotypes of DCs were also assessed by FACS analysis with the following antibodies: H-2K d , I-A d , CD40, CD54, CD80 and CD86. Phenotypic characterization of activated T cells: A total of 5 Â 10 6 splenocytes from mice 2 weeks after treatment of AdVCD40L and iDCs were cocultured with 2 Â 10 5 irradiated J558 cells in 24-well plates. After 4 days, the activated T cells were purified from the cultures using Ficoll-Paque density gradient centrifugation and analyzed by flow cytometry using the following antibodies: CD4, CD8, CD25, CD40L, CD69 or FasL.
Detection of apoptosis and endocytic analysis
After transfected with AdVCD40L, apoptosis of J558 cells was measured by cell staining with FITC-Annexin-V antibody and propidium iodide according to the manufacturer's instruction. The uptake of apoptotic bodies derived from tumor cells by DCs was evaluated by the technique described by Albert et al. 27 Briefly, DCs were dyed green using CMFDA (492 nm/516 nm, Molecular Probes, Eugene, OR) and cocultured with J558/CD40L (1:1 ratio) stained red using CM-DiI (553 nm/570 nm, Molecular Probes, Eugene, OR). Flow cytometric analysis was performed at the 24-hour time point and doublepositive cells enumerated.
Animal studies
BALB/c mice (10 per group) were subcutaneously (s.c.) inoculated in their right thighs with 0.3 Â 10 6 viable J558 tumor cells. After 7 days, when tumors reached 3-4 mm in diameter, 30 ml AdVCD40L or AdVpLpA at 5 Â 10 9 PFU was intratumorally injected. At 2 days after adenovirus administration, the intratumor injection of iDCs at 1 Â 10 6 cells per mouse was conducted. Tumor growth was monitored every other day by measuring two perpendicular tumor diameters using a caliper. Animals showing severe distress or with tumors that exceeded 1.5 cm in diameter were killed for ethical reasons according to the institutional guidelines. Animals were monitored for a total of 60 days. To study the protective immunity, 2 months later, mice with tumor regression were rechallenged with s.c. injection of 0.3 Â 10 6 J558 or SP2/0 tumor cells.
To investigate the responsibility of T-cell subsets in the protective immunity induced by intratumoral cotreatment with AdVCD40L and iDCs, we monitored the tumor growth and survival period of T-cell subset depleted mice. In vivo depletion experiments were performed as described. 28 Briefly, BALB/c mice (10 per group) were i.p. injected with anti-CD4 (Gk1.5 hybridoma) or anti-CD8 (3.155 hybridoma) antibodies, respectively, at 0.5 mg per mouse 2 days prior to, 1, 3, and 5 days subsequent to the intratumoral injection of adenovirus. As a control, one group of mice was injected with the same amount of irrelevant isotype-matched rat IgG. Mice were monitored for tumor progression or regression. Depletion of T-cell subsets was monitored by flow cytometry, which showed 490% specific depletion in splenocytes (data not shown).
Histological examination
Tumor nodules at the injection sites were removed for histological analysis 1, 2 or 3 days after the injection of AdVCD40L. The tumor samples were fixed in 10% formaldehyde and embedded in paraffin. Sections of 7 mm thickness were stained with hematoxylin-eosin according to the standard procedures.
Cytotoxicity assay
At 2 weeks after treatment of AdVCD40L and iDCs, splenic lymphocytes from mice were isolated and stimulated in vitro for 4 days with irradiated J558 cells. Cells were then collected as CTL effector cells in a chromium-release assay. Target cells included J558 and SP2/0 tumor cells, which were radiolabeled with [
51 Cr]-chromate. A total of 10,000 labeled target cells per well were mixed with effector cells at various effector/target cell ratios in triplicate and incubated for 6 hours. Percentage of specific lysis was calculated as: 100 Â [(experimental CPM-spontaneous CPM)/(maximal CPMspontaneous CPM)]. Spontaneous count per minute (CPM) released in the absence of effector cells was less than 10% of specific lysis. The maximal CPM was released by adding 1% Triton X-100 to wells in the experiment.
Assay of cytokine production
At 2 weeks after treatment of AdVCD40L and iDCs, splenocytes from mice were isolated and co-cultured in vitro for 4 days with irradiated J558 cells. The supernatants were harvested at day 1 or day 3 for measurement of IFN-g or IL-4 secretion. The amounts of cytokines were determined using a standard sandwich ELISA technique with corresponding kits from Endogen (Endogen, Woburn, MA, USA).
Statistical analysis
All the experiments were run in triplicate and the results are expressed as means 7 SD (or representative data from two or three independent experiments). Statistical analysis was performed using the Student's t-test and logrank test (for survival analysis). The difference was considered statistically significant when the P-value was less than .05.
Results
Efficient stimulation of costimulatory molecules on J558 cells after transfection with AdVCD40L
The expression of CD40, CD40L, CD80, CD86, H-2K d , I-A d or Fas on J558 cells or J558/pLpA or J558/CD40L was analyzed by FACS. As shown in Figure 1 , J558/ CD40L cells expressed high level of CD40L, whereas the unmodified J558 and J558/pLpA cells showed no CD40L expression. Moreover, the expressions of costimulatory molecules such as CD80, CD86 and MHC class I, MHC class II on J558/CD40L were much higher than those on untransfected J558 or J558/AdVpLpA cells. In addition, the Fas molecule was also highly upregulated after AdVCD40L transfection. The results indicated that AdVCD40L vector could efficiently mediate the expression of CD40L and upregulate the expressions of MHC class I, costimulatory and adhension molecules.
Potent induction of J558 cell apoptosis by AdVCD40L transfection
To examine whether the AdVCD40L transfection could induce tumor cell apoptosis, flow cytometry analysis was performed using Annexin-V and propidium staining. The results showed that the apoptotic rate of J558/CD40L cells was significantly increased after transduction with the AdVCD40L compared with untransfected J558 or J558/pLpA cells (62.5% vs. 14.9%, 25.7%) (Fig 2) . Consistently, histological examination also confirmed that the existence of multiple areas of apoptosis in tumor nodules from mice 2 days after injection of AdVCD40L in vivo (Fig 3) .
iDCs could effectively uptake apoptotic bodies and be induced maturation by J558/CD40L
Since the J558/CD40L cells contained a population of apoptotic cells, the uptake of apoptotic bodies derived Figure 4 , the percent of double positive cells was 32.3 and 61.5% after interaction with J558/CD40L for 4 or 24 hours, respectively. CD40L transduction could significantly induce the apoptosis of J558 cells. Moreover, iDCs could uptake the apoptotic cells powerfully. Thus, we further investigated whether the cocultivation with J558/CD40L could increase the expression of costimulatory molecules on iDCs and stimulate their maturation. As shown in Figure 5a , I-A d , costimulatory molecules and adhension molecules (CD40, CD80, CD86, CD54) were significantly upregulated on DCs cocultured with J558/CD40L for 2 days, compared with those on DCs cocultivated with untransfected J558 cells or J558/pLpA.
In addition, DCs recovered after coculture with J558/ CD40L significantly increased the proliferation of autologous spleen T cells assessed by MLR compared to DCs from other two groups (Fig 5b) .
More effective induction of therapeutic antitumor immunity by cotreatment with iDCs following AdVCD40L
The experiments above suggested that intratumoral injection iDCs following AdVCD40L could possibly elicit potent antitumor response in vivo. Therefore, we investigated the therapeutic efficacy of the combined AdVCD40 with iDCs vaccine in pre-existing J558 tumors models. As shown in Figure 6 , vaccination with iDCs alone failed to inhibit the rapid tumor growth. Although AdVCD40L-mediated gene therapy significantly reduced tumor growth, it still could not eradicate tumors in any mice bearing J558 tumors, whereas a combined AdVCD40L-mediated gene therapy with iDCs vaccine led to 40% of mice tumor free.
To examine whether the tumor regression of combined treatment could result in protective immunity against the wild-type J558 tumor, eight mice that experienced tumor regression were rechallenged with the parental J558 or SP2/0 tumor cells. We found that no J558 tumor growth was found in mice with tumor regression after the combination treatment, while the tumor growth of irrelevant SP2/0 tumor cell line occurred in all these immunized mice (data not shown). The results illustrated that mice with tumor regression after the combined treatment with AdVCD40L and iDCs induced a specific protective immune response against the parental J558 tumor, but not against the irrelevant SP2/0 tumor, indicating that mice had developed a solid tumor-specific immunologic memory after tumor regression.
Significantly enhanced CTL response by intratumoral coinjection of AdVCD40L and iDCs
Splenic lymphocytes from mice 2 weeks after treatment of AdVCD40L and iDCs were stimulated with irradiated J558 cells in vitro for 4 days. The cytotoxic activities of CTL was determined by chromium release assay. As shown in Figure 7 , CTL of mice treated with AdVCD40L and iDCs showed much higher specific activity compared to that of mice treated with AdVCD40L only (52% vs. 14 
Efficiently upregulate FasL expression on activated T cells and induce type 1 antitumor immune responses after intratumoral coinjection of AdVCD40L and iDCs
To further elucidate the immune mechanism involved in the therapeutic immunity of AdVCD40L and iDCs vaccine, splenocytes from mice 2 weeks after intratumoral coinjection with AdVCD40L and iDCs were stimulated with irradiated J558 tumor cells for 4 days, and activated T cells were prepared. These T cells were then subjected to phenotypic characterization by flow cytometry. As shown in Figure 8 , the activated T cells derived from mice treated with AdVCD40L and iDCs displayed higher expressions of T cell active marker (CD25) and costimulatory molecules CD40L and when compared with that of T cells from control mice. Interestingly, FasL molecule was also significantly upregulated. The induction of antitumor immunity and tumor growth has been shown to be associated with the enhancement of Th1 immune response. 24 To examine the type of T-cell response derived from AdVCD40L and iDCs vaccination, the expression of IFN-g and IL-4 were measured in the supernatants of the activated T cells using cytokine ELISA kits. The results demonstrated that activated tumor-specific T cells secreted high level of IFN-g (2.5 and 3.6 ng/ml at Day 1 and Day 3, respectively), while IL-4 could not be detected (data not shown). The profile of cytokine secretion was thus consistent with a type I T-cell response. þ , 30% tumor free; control IgG, 40% free) (Fig 9) . These data suggested that both CD4 þ and CD8 þ T cells might be involved in mediating the antitumor immune responses of combined treatment of AdVCD40L and iDCs, with CD8 þ T cells being the major effectors.
Discussion
To induce most antitumor efficacy and elucidate the appropriate conditioning of DCs for anticancer immunotherapy and related mechanism, we conducted two studies on J558 tumor cells. The first was studying the direct function of AdVCD40L on the J558 tumor cells and its indirect function on iDCs in vitro; the other was studying the synergizing antitumor efficacy of intratumoral administration of iDCs following AdVCD40L iDCs could induce a type 1 immune response and increase the cytotoxicity of J558-tumor-specific CTL. T-cell subset depletion assay showed that the antitumor activity of CD40L gene therapy combined with iDCs vaccine was completely diminished in mice depleted of CD8 þ T cells, and partially abrogated by depletion of CD4 þ T cells. This suggested that both CD4 þ and CD8 þ T cells might be involved in mediating the antitumor immune responses in this therapeutical model, with CD8 þ T cells being the critical effectors.
It has been reported that CD40L is able to increase the expression of a number of adhesion and costimulatory molecules through its interaction with CD40 on B cells or APCs. 29 This phenotypic change also has functional consequences, because this interaction makes B cells better APCs and increases their capacity to stimulate T cells. 30 This effect has been demonstrated not only in normal B cells but also in lymphoma B cells as well. [31] [32] [33] In our study, we have shown that J558 myeloma cells, transfected with a recombinant adenovirus encoding CD40L, can significantly upregulate several costimulatory molecules that may potentially convert those cells into better APCs and stimulate tumor antigen-specific T cells. [34] [35] [36] The functions of DCs are distinct in the processes of its development. Either in the initiation phase or in the effector phase, different outcomes could be obtained by providing with CD40 stimulation and the duration of stimulation. Consistent with other report, 15 the usage of iDCs for the priming phase could provide significant advantages in anticancer immunotherapy. In this study, we fully utilized the dual biological characteristics of DCs, that is, iDCs have the highest engulfing function to uptake the tumor apoptotic bodies and iDCs undergoing maturation by stimulating of CD40L in the tumor micro environmental possess the highest migratory activity to be able to effectively activate specific antitumor CTL. Figure 7 Cytotoxicity assay. To induce CTL, splenocytes from mice 2 weeks after treatment of AdVCD40L and iDCs were stimulated in vitro for 4 days with irradiated J558 cells. Those CTL (K) were used as effector cells in chromium release assays, in which 51 Cr-labeled J558 tumor cells were used as target cells. To confirm that CTL was J558 tumor specific, we also included SP2/0 cells (J) as a target control. CTL from mice inoculated with irradiated AdVCD40L were used as an effector control (') in chromium release assays, in which 51 Cr-labeled J558 tumor cells were used as target cells. One representative experiment of two is shown. Figure 8 Phenotypic analysis of J558 tumor-specific T cells. Splenic lymphocytes from mice 2 weeks after treatment of AdVCD40L and iDCs were stimulated in vitro for 4 days with irradiated J558 cells (activated T cells), then immunostained for assessment of multiple markers by flow cytometry using specific antibodies. Unstimulated T cells from naïve mice were used as negative control cells (naïve T cells). Cell surface CD4, CD8, CD25, CD40L, and FasL were detected using marker specific primary antibodies (solid lines) or isotype-matched irrelevant control antibodies (dotted lines) and FITC-conjugated secondary antibodies.
One of the effects of CD40L interaction on J558 cells is the upregulation of the Fas molecule, which is beneficial for enhancing the sensitivity of the tumor cells to apoptosis by interaction with FasL. Noteworthily, our results demonstrated that high expression of FasL was detected on the activated T cells prepared by splenocytes from mice 2 weeks after intratumoral treatment with AdVCD40L and iDCs vaccine coculturing irradiated J558 cells. These apoptotic cells and those directly induced by the CD40L could be uptaken by the iDCs that in turn activate tumor-specific T cells, resulting in enhanced the antitumor efficacy of AdVCD40L and iDCs vaccine.
In summary, our data demonstrated that adenovirusmediated CD40L gene therapy could induce CD40 þ myeloma cell apoptosis and favor maturation of iDCs through capturing the apoptotic cells, efficiently increase the killing activity of tumor specific T lymphocytes and Th1 immune response. The combination of intratumor administration of iDCs following AdVCD40L as a vaccine can elicit a strong antitumor immune response, indicating that sequentially administration of CD40L and iDCs could be a better paradigm for antitumor therapy. 
